Nuvalent
study design a global phase study of in patients with advanced positive and other solid tumors cane | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
11 of 31
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
a global first in human phase clinical trial of in advanced positive and other solid tumors dose preliminary data presented all treated population enrollment completed august updated data to be presented at medical meeting patient population harboring fusions by local testing prior for no limit to number prior chemotherapies or excluded concurrent drivers alk met ret or evaluable but non measurable disease allowed objectives enrollment initiated data as for patients treated by dose cohorts all doses dose expansion for dose optimization all treated population response evaluable population selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity central nervous system dose toxicities milligram maximum tolerated dose non small cell lung cancer once daily recommended with concurrent evaluation per protocol an patients drivers identified on plan tyrosine kinase testing patients without measurable disease are excluded from efficacy first response evaluation is pending patients response evaluable population prospect defined as all patients with measurable disease without concurrent driver who post response assessment treatment due progression death prior to the first response additional patients for no measurable tumor with alternate driver met amplification discontinued study treatment prior to first response assessment tumor pancreatic cancer source | Nuvalent
Investor Presentation
April 2024
a global first in human phase clinical trial of in advanced alk positive and other solid tumors dose preliminary data presented all treated population enrollment completed updated data to be presented at medical meeting enrollment initiated june data cut off dose cohorts all doses patient population dose harboring alk fusion or activating mutation by local testing patients with prior or alk for dose optimization prior chemotherapies all treated population excluded concurrent drivers met ret or evaluable but non measurable disease allowed response evaluable population objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity non small cell with cor evaluation per i platinum base dor duration response maximum cancer objective rate overall survival on free survival dose tyrosine kinase drivers identified on subsequent testing patients without measurable disease are excluded from efficacy time to response inhibitor without prior to the first response for response no measurable disease at tumor with driver met amplification no post scan discontinued treatment for reasons than tumor pancreatic atypical carcinoid lung source lin | Nuvalent
Investor Presentation
February 2024
a global first in human phase clinical trial of in advanced positive and other solid tumors dose preliminary data presented all treated population enrollment completed august updated data to be presented at medical meeting patient population harboring fusions by local testing prior for no limit to number prior chemotherapies or excluded concurrent drivers alk met ret or evaluable but non measurable disease allowed objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity enrollment initiated data as for patients treated by dose cohorts all doses dose expansion for dose optimization all treated population response evaluable population need i central nervous system dose limit once daily recommended patients with concurrent evaluation per toxicities milligram maximum tolerated tyrosine kinase identified on subsequent testing patients without measurable disease are excluded from efficacy ose non small cell lung cancer first response evaluation is pending response evaluable population prospectively defined as all patients with measurable disease without concurrent treatment due to progression death prior to the first tumor with altern driver met discontinued study treatment prior to first assessment tumor pancreatic cancer | Nuvalent
Investor Presentation
February 2024
a global first in human phase clinical trial of in advanced alk positive and other solid tumors dose preliminary data presented all treated population enrollment completed updated data to be presented at medical meeting enrollment initiated june data cut off dose cohorts all doses patient population dose harboring alk fusion or activating mutation by local testing patients with prior or alk for dose optimization prior chemotherapies all treated population excluded concurrent drivers met ret or evaluable but non measurable disease allowed response evaluable population objectives selection if applicable primary overall safety tolerability characterization preliminary activity intracranial activity on alk clinic non generation alk i rate i platinum base dor duration response maximum cancer objective survival progression free survival with cor evaluation per first response me to response evaluable population prospectively defined as all patients with at tumor scan discontinued treatment for reasons than tumor tic atypical carcinoid lung source lin | Nuvalent
Related slides by other companies
ATAI
Investor Presentation
January 2024
demonstrated safety level and plasma concentrations of in line with previous trials potential therapeutic plasma levels no serious adverse events reported asymptomatic prolongation phase study trial design results summary | ATAI
ATAI
Investor Conference
May 2023
phase trial design randomized week study of and placebo in patients with | ATAI
Matinas BioPharma
Investor Presentation
February 2024
agreed phase study design in invasive aspergillosis the trial | Matinas BioPharma
BioAtla
Investor Presentation
November 2022
phase study design with | BioAtla
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
January 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io